Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has acquired Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma, it was reported yesterday.
Farmax has been renamed Neuraxpharm Bohemia and will commercialise its products under the Neuraxpharm brand. Neuraxpharm Bohemia plans to offer new and differentiated products to local patients and healthcare providers based on the group's broad CNS range.
The terms of the deal were not revealed.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials